Cargando…

Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis

BACKGROUND: International guidelines recommend using basal insulin in patients with type-2 diabetes mellitus if glycaemic target cannot be attained on non-insulin anti-diabetic drugs. Available choices of basal insulin include intermediate-acting neutral protamine Hagedorn (NPH) insulin and long-act...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lau, E., Salem, A., Chan, J. C. N., So, W. Y., Kong, A., Lamotte, M., Luk, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604305/ https://www.ncbi.nlm.nih.gov/pubmed/31303866 http://dx.doi.org/10.1186/s12962-019-0180-9

Ejemplares similares

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study
por: Rosenstock, J., et al.
Publicado: (2009)

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
por: Rosenstock, J., et al.
Publicado: (2009)

Cost Effectiveness of Insulin Glargine versus Neutral Protamin Hagedorn Insulin in the Treatment of Type 2 Diabetes Patients in Turkey
por: Satman, Ilhan, et al.
Publicado: (2013)

A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus
por: Liu, Min, et al.
Publicado: (2016)

Switching from Neutral Protamine Hagedorn (NPH) Insulin to Insulin Glargine 300 U/mL in Older and Younger Patients with Type 2 Diabetes: A Post Hoc Analysis of a Multicenter, Prospective, Observational Study
por: Wolnik, B., et al.
Publicado: (2022)

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Reply to Chantelau E [letter] and Currie CJ [letter]
por: Rosenstock, J., et al.
Publicado: (2009)

Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
por: Morales, Cristóbal, et al.
Publicado: (2015)

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes
por: Home, P D, et al.
Publicado: (2015)

Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study
por: Wang, Li, et al.
Publicado: (2013)

Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients
por: Ling, James, et al.
Publicado: (2021)

Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A(1)chieve study
por: Wangnoo, Subhash Kumar, et al.
Publicado: (2014)

Long‐term field study of lispro and neutral protamine Hagedorn insulins treatment in dogs with diabetes mellitus
por: Kuzi, Sharon, et al.
Publicado: (2023)

Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review
por: Hagenmeyer, Ernst-Günther, et al.
Publicado: (2011)

Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain
por: Delgado, E
Publicado: (2012)

A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes
por: Hod, Moshe, et al.
Publicado: (2014)

Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study
por: Wolnik, B., et al.
Publicado: (2020)

Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study
por: ji, Jing, et al.
Publicado: (2020)

Comparison of Insulin Lispro Protamine Suspension with NPH Insulin in Pregnant Women with Type 2 and Gestational Diabetes Mellitus: Maternal and Perinatal Outcomes
por: Colatrella, Antonietta, et al.
Publicado: (2013)

Comparison of the Efficacy and Safety of Insulin Glargine and Insulin Detemir with NPH Insulin in Children and Adolescents with Type 1 Diabetes Mellitus Receiving Intensive Insulin Therapy
por: Dündar, Bumin Nuri, et al.
Publicado: (2009)

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus
por: Porcellati, Francesca, et al.
Publicado: (2011)

A Randomized Clinical Trial of Insulin Glargine and Aspart, Compared to NPH and Regular Insulin in Children with Type 1 Diabetes Mellitus
por: Rostami, Parastoo, et al.
Publicado: (2014)

Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin
por: Stürmer, Til, et al.
Publicado: (2013)

Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus
por: Fournier, Marie, et al.
Publicado: (2014)

Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly
por: Varewijck, A. J., et al.
Publicado: (2012)

The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range
por: Elhabashy, Safinaz Adel, et al.
Publicado: (2023)

Neutral protamine hagedorn/regular insulin in the treatment of inpatient hyperglycemia: Comparison of 3 basal-bolus regimens
por: Quintanilla-Flores, Dania Lizet, et al.
Publicado: (2017)

Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
por: Sharplin, Peter, et al.
Publicado: (2009)

Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus
por: Eledrisi, Mohsen, et al.
Publicado: (2018)

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes
por: Forst, T, et al.
Publicado: (2010)

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
por: Johansen, Odd Erik, et al.
Publicado: (2009)

Quality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin: A Systematic Review and Policy Implications
por: Almeida, Paulo H. R. F., et al.
Publicado: (2018)

Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
por: Lepercq, Jacques, et al.
Publicado: (2012)

Glycemic Control in Hospitalized Patients with Diabetes Receiving Corticosteroids Using a Neutral Protamine Hagedorn Insulin Protocol: A Randomized Clinical Trial
por: Khowaja, Ameer, et al.
Publicado: (2018)

Replacement of neutral protamine Hagedorn insulin with the long‐acting insulin analogue, detemir, improves glycemic control without weight gain in basal–bolus insulin therapy in Japanese patients with type 1 diabetes
por: Hayakawa, Taro, et al.
Publicado: (2011)

All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine
por: Strandberg, Arto Y., et al.
Publicado: (2016)

Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus
por: Rys, Przemyslaw, et al.
Publicado: (2015)

Basal Supplementation of Insulin Lispro Protamine Suspension Versus Insulin Glargine and Detemir for Type 2 Diabetes: Meta-analysis of randomized controlled trials
por: Esposito, Katherine, et al.
Publicado: (2012)

Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach
por: Pollock, Richard F, et al.
Publicado: (2018)

Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes
por: Suzuki, Katsunori, et al.
Publicado: (2016)

The Use of Protamine Insulin
por: Nixon, J. A.
Publicado: (1938)

Cannot write session to /tmp/vufind_sessions/sess_0ff7ajiaou5u9dprg48b7rhg6k